Biblio
“Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins.”, J Alzheimers Dis, p. 13872877241313031, 2025.
, “Leptin, adiponectin, body mass index, and incident cognitive impairment.”, J Alzheimers Dis, p. 13872877251326060, 2025.
, “Lifespan of male and female APP/PS1 and APP mouse models of Alzheimer's disease.”, J Alzheimers Dis, p. 13872877251325878, 2025.
, “Lipopolysaccharides from indirectly induce neuronal GSK3β-dependent synaptic defects and cause cognitive decline in a low-amyloid-β-concentration environment in Alzheimer's disease.”, J Alzheimers Dis, p. 13872877251326879, 2025.
, “Medications and cognitive decline in Alzheimer's disease: Cohort cluster analysis of 15,428 patients.”, J Alzheimers Dis, p. 13872877241307870, 2025.
, “The potential impact of optimal blood pressure treatment intensity to reduce disparities in dementia between Black and White individuals.”, J Alzheimers Dis, p. 13872877241302506, 2025.
, “Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.”, J Alzheimers Dis, p. 13872877251329439, 2025.
, “Sex-specific effects of apolipoprotein E ε4 genotype on longitudinal hippocampal atrophy in amnestic mild cognitive impairment over a 2-year evaluation period.”, J Alzheimers Dis, p. 13872877241313066, 2025.
, “White matter lesions rather than amyloid-β burden are associated with cognitive decline in Alzheimer's disease.”, J Alzheimers Dis, p. 13872877251316516, 2025.
,